Children treated with peginterferon alpha (pegIFN (and) #945;) for hepatitis C (HCV) display significant changes in height, weight, body mass index (BMI), and body composition. This was found out by a follow-up research from the Pediatric Study of Hepatitis C (PEDS-C) trial . Results appearing in the August issue of iHepatology/i, a journal of the American Association for the Study of Liver Diseases, indicate that most growth-related side effects are reversible with cessation ...
via Medindia Health News
More READ
No comments:
Post a Comment